"Following the 2014 Ebola outbreak in West Africa that took the lives of more than 11,200 people in the region, the National Eye Institute, part of the National Institutes of Health, has deployed a team of clinicians and technical experts to Monro"...
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. IZBA (travoprost ophthalmic solution) 0.003% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.
Reduction of the intraocular pressure starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.
IZBA may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Dosage Forms And Strengths
Ophthalmic solution containing travoprost 0.03 mg/mL.
Storage And Handling
IZBA (travoprost ophthalmic solution) 0.003% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.03 mg/mL) supplied in Alcon's oval DROP-TAINER® package system.
IZBA is supplied as a 2.5 mL solution in a 4 mL bottle and a 5 mL solution in a 7.5 mL bottle. The dispenser bottles are made of polypropylene and fitted with a natural color polypropylene dropper tip and a turquoise polypropylene overcap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.
2.5 mL fill NDC 0065-0000-00
5 mL fill NDC 0065-0000-00
Store at 2° -25°C (36° -77°F).
Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA. Revised: May 2014This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/29/2014
Additional Izba Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.